Not Medicare Enrolled
Dr. William Harwin, M.D.
Hematology · Fort Myers, FL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Harwin from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Harwin?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Harwin
Dr. William Harwin is a hematology specialist in Fort Myers, FL, with 20 years of NPI registration. Based on federal Medicare data, Dr. Harwin performed 85,686 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Harwin received a total of $68,047 from 59 pharmaceutical and/or device companies across 257 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Harwin is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 50% volume in FL
$68,047 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗85,686
Medicare services
Top 50% in FL for hematology
Not available
Unique patients (not deduplicated)
$17
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 18,200 | $43 | $137 |
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
17,340 | $0 | $4 |
| Anti-nausea injection (aprepitant) | 11,440 | $1 | $5 |
| Nivolumab injection (Opdivo) | 9,820 | $24 | $72 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
7,590 | $6 | $23 |
| Denosumab injection (Prolia/Xgeva) | 7,140 | $18 | $51 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,926 | $0 | $3 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,469 | $8 | $29 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,288 | $8 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,230 | $1 | $28 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,034 | $97 | $339 |
| Injection, fulvestrant, 25 mg | 960 | $9 | $132 |
| Injection, leucovorin calcium, per 50 mg | 626 | $3 | $12 |
| Anti-nausea injection (ondansetron/Zofran) | 464 | $0 | $9 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
438 | $12 | $61 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
428 | $2 | $7 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
426 | $101 | $378 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
403 | $11 | $69 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
214 | $71 | $239 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
183 | $48 | $189 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
179 | $22 | $84 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
175 | $10 | $42 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
152 | $1 | $3 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
142 | $2 | $7 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
136 | $6 | $69 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
122 | $16 | $56 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
121 | $26 | $89 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 107 | $135 | $562 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
104 | $17 | $59 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
95 | $25 | $156 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
95 | $57 | $206 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
81 | $44 | $170 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
80 | $22 | $79 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
75 | $1 | $6 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
71 | $50 | $178 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
49 | $131 | $637 |
| Automated urinalysis An automated laboratory test performed on a urine sample to analyze its chemical and physical properties. The procedure uses machinery to detect various substances and cells within the urine. |
47 | $2 | $8 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
47 | $29 | $156 |
| Methylprednisolone injection, up to 40 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, administered in a dose of up to 40 mg. |
42 | $3 | $11 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
40 | $16 | $56 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
33 | $1 | $7 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
26 | $145 | $474 |
| New patient office visit, complex (60-74 min) | 20 | $171 | $585 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
16 | $46 | $147 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
12 | $136 | $453 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
21.7% high complexity
73.0% medium
5.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$68,047
Total received (2018-2024)
Avg $9,721/year across 7 years
Top 8% in FL for hematology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
59
Companies
257
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$19
2023
$617
2022
$1,684
2021
$1,806
2020
$36,023
2019
$20,422
2018
$7,478
Payments by company (2024)
E.R. Squibb & Sons, L.L.C.
$19
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
Daiichi Sankyo Inc.
$25,581
GENZYME CORPORATION
$9,084
TESARO, Inc.
$7,148
AstraZeneca Pharmaceuticals LP
$5,867
Seattle Genetics, Inc.
$3,555
EISAI INC.
$2,623
Karyopharm Therapeutics Inc.
$2,291
Eisai Inc.
$1,875
BeiGene USA, Inc.
$1,650
E.R. Squibb & Sons, L.L.C.
$1,224
Ipsen Bioscience Inc
$850
Janssen Scientific Affairs, LLC
$650
Amgen Inc.
$576
Celgene Corporation
$546
BeiGene, Ltd.
$450
Heron Therapeutics, Inc.
$404
Foundation Medicine, Inc.
$300
Ipsen Biopharmaceuticals, Inc
$287
Merck Sharp & Dohme Corporation
$277
Janssen Biotech, Inc.
$273
Incyte Corporation
$262
Gilead Sciences, Inc.
$222
Lilly USA, LLC
$143
ADC Therapeutics America, Inc.
$125
Genentech USA, Inc.
$118
Epizyme, Inc.,
$117
Seagen Inc.
$116
Bayer HealthCare Pharmaceuticals Inc.
$115
Siemens Medical Solutions USA, Inc.
$110
Verastem, Inc.
$109
Johnson & Johnson Health Care Systems Inc.
$100
Exelixis Inc.
$99
Array BioPharma Inc.
$97
AmerisourceBergen Drug Corporation
$93
Cardinal Health 110, LLC
$83
GlaxoSmithKline, LLC.
$65
Pharmacyclics LLC, An AbbVie Company
$59
Novartis Pharmaceuticals Corporation
$53
CTI BioPharma Corp.
$42
Eli Lilly and Company
$40
CSL Behring
$38
EMD Serono, Inc.
$36
Regeneron Healthcare Solutions, Inc.
$26
Merck Sharp & Dohme LLC
$26
Astellas Pharma US Inc
$23
Pharmacyclics LLC, an AbbVie Company
$23
SERVIER PHARMACEUTICALS LLC
$21
MorphoSys, US Inc.
$20
Alnylam Pharmaceuticals Inc.
$18
SANOFI-AVENTIS U.S. LLC
$18
SOBI, INC
$17
Agios Pharmaceuticals, Inc.
$15
Sumitomo Pharma America, Inc.
$13
Helsinn Therapeutics (U.S.), Inc.
$13
Kyowa Kirin, Inc.
$13
Rigel Pharmaceuticals, Inc.
$12
PFIZER INC.
$12
Partner Therapeutics, Inc.
$11
GE HEALTHCARE
$9
Top 3 companies account for 61.4% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AKYNZEO · Abraxane · Alecensa · Aliqopa · BRUKINSA · Bavencio · Biograph mCT · Blincyto · CABOMETYX · CALQUENCE · CD38 · CINVANTI · CYMBALTA · CYRAMZA · Copiktra · DARZALEX · Doptelet · EMPLICITI · ENHERTU · ERLEADA · Enhertu · Erleada · FOUNDATIONONE LIQUID · GAZYVA · Halaven · IMBRUVICA · Idelvion · Imbruvica · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · Kadcyla · Kyprolis · LENVIMA · LIBTAYO · LUMAKRAS · LYNPARZA · Lenvima · Leukine · MONJUVI · Neulasta · Nplate · ONPATTRO · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · POTELIGEO · PROMACTA · Phesgo · Pomalyst · REBLOZYL · RYBREVANT · Revlimid · SARCLISA · SOMATULINE DEPOT · SPRYCEL · TAGRISSO · TAZVERIK · TIBSOVO · TUKYSA · Tavalisse · Tibsovo · Trodelvy · VERZENIO · Vonjo · XGEVA · XPOVIO · XTANDI · ZEJULA
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematologists in nearby ZIP areas
15
County median income
$73,099
Nearest hospital to ZIP centroid (approximate)
PARK ROYAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | — Not enrolled | N/A |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Harwin is a mixed practice specialist, with moderate Medicare volume, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Harwin experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Harwin performed 18,200 pembrolizumab injection (keytruda) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Harwin receive payments from pharmaceutical companies?
Yes. Dr. Harwin received a total of $68,047 from 59 companies across 257 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Harwin's costs compare to other hematologists in Fort Myers?
Dr. Harwin's average Medicare payment per service is $17. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Harwin) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologists in Fort Myers
Browse hematologists in Fort Myers ranked by procedure volume and transparency data.
Highest volume
Top Hematologists in FL
Hematologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologists in FL
Which FL hematologists receive the most from drug and device companies.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
By company
TESARO, Inc. Payments to Doctors
See all physicians who received payments from TESARO, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology